Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma 23Burkitt Lymphoma 23Multiple Myeloma 20Lymphoma, Non-Hodgkin 17Leukemia, Myeloid, Acute 16Lymphoma, Follicular 15Myelodysplastic Syndromes 14Lymphoma, Mantle-Cell 14Leukemia, Biphenotypic, Acute 14Lymphoma, B-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell 9Hodgkin Disease 9Lymphoma, B-Cell, Marginal Zone 8Neuroblastoma 7Glioma 7Wilms Tumor 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Central Nervous System Neoplasms 6Rhabdoid Tumor 5Primary Myelofibrosis 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Myeloproliferative Disorders 5Mycosis Fungoides 5

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × Specimen Handling × Lymphoid × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡